IRSN, Institut de radioprotection et de sûreté nucléaire

Search our site :


Contact us :

En Fr

Enhancing Nuclear Safety

Send Print

Contribution of IRSN to the review of the Safety Options for the ATMEA1 reactor

From 2010 to 2011, IRSN had carried out a technical review of the safety options for the ATMEA1 reactor. The ATMEA1 reactor is a Generation III pressurized water reactor with rated power of 1000 MWe developed by the company ATMEA, subsidiary of Areva and Mitsubishi Heavy Industries. Based on the review by IRSN, the French Nuclear Safety Authority (ASN) issued in February 2012 a positive opinion on the safety options of this reactor.

The review by IRSN had two distinct phases:

  • Phase 1: review of the safety options for ATMEA1 reactor in order to draw up a list of issues to be addressed in detail during Phase 2 together with the list of necessary support documents
  • Phase 2: review of the Safety Options Report and complementary reports on issues identified during Phase 1.

The first phase resulted in 10 reports considered at meetings of the Reactor Safety Advisory Committee (GPR), the meetings took place in 2011. In this context, IRSN also discussed a review program in relation with the first lessons learned from the accident at the Fukushima Daiichi power plant (Japan). In addition, to supplement the GPR review, a review of aircraft hazards safety options regardless their type or origin was carried out.

This significant investment from IRSN in the review of the ATMEA1 reactor has enabled the Institute to develop a strong expertise about the new reactor, expertise that will assist, where appropriate, foreign regulators and technical safety organizations (TSO) in the context of a request for authorization to create a reactor ATMEA1.

Download the summary of the safety options review performed by IRSN for the ATMEA1 reactor (PDF)

Back to all the news


Send to a friend

The information you provide in this page are single use only and will not be saved.
* Required fields

Recipient's email:*  

Sign with your name:* 

Type your email address:*   

Add a message :

Do you want to receive a copy of this email?